257 related articles for article (PubMed ID: 29520657)
1. SOX11 expression as a MRD molecular marker for MCL in comparison with t(11;14) and IGH rearrangement.
Szostakowska M; Szymczyk M; Badowska K; Tudek B; Fabisiewicz A
Med Oncol; 2018 Mar; 35(4):49. PubMed ID: 29520657
[TBL] [Abstract][Full Text] [Related]
2. SOX11 as a minimal residual disease marker for Mantle cell lymphoma.
Simonsen AT; Sørensen CD; Ebbesen LH; Bødker JS; Bentzen HH; Nyvold CG
Leuk Res; 2014 Aug; 38(8):918-24. PubMed ID: 24878000
[TBL] [Abstract][Full Text] [Related]
3. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VH; van Dongen JJ; Kneba M
Methods Mol Biol; 2013; 971():175-200. PubMed ID: 23296964
[TBL] [Abstract][Full Text] [Related]
4. Common consensus LNA probe for quantitative PCR assays in cancer: vehicles for minimal residual disease detection in t(11;14) and t(14;18) positive malignant lymphomas.
Sørensen CD; Jørgensen JM; Nederby L; Hokland P; Nyvold CG
J Immunol Methods; 2014 Apr; 406():131-6. PubMed ID: 24631717
[TBL] [Abstract][Full Text] [Related]
5. A highly sensitive and specific qPCR assay for quantification of the biomarker SOX11 in mantle cell lymphoma.
Hamborg KH; Bentzen HH; Grubach L; Hokland P; Nyvold CG
Eur J Haematol; 2012 Nov; 89(5):385-94. PubMed ID: 22827557
[TBL] [Abstract][Full Text] [Related]
6. The role of SOX11 in mantle cell lymphoma.
Lu TX; Li JY; Xu W
Leuk Res; 2013 Nov; 37(11):1412-9. PubMed ID: 24001358
[TBL] [Abstract][Full Text] [Related]
7. Detection of t(12;14)(p13;q32) in a patient with IGH-CCND1 negative mantle cell lymphoma resembling ultra-high risk chronic lymphocytic leukemia.
Miao Y; Wang R; Fan L; Qiu H; Wu Y; Chen Y; Xu W; Li J
Int J Clin Exp Pathol; 2015; 8(6):7494-8. PubMed ID: 26261659
[TBL] [Abstract][Full Text] [Related]
8. miR-223 is repressed and correlates with inferior clinical features in mantle cell lymphoma through targeting SOX11.
Zhou K; Feng X; Wang Y; Liu Y; Tian L; Zuo W; Yi S; Wei X; Song Y; Qiu L
Exp Hematol; 2018 Feb; 58():27-34.e1. PubMed ID: 29158064
[TBL] [Abstract][Full Text] [Related]
9. Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang.
Gimenez E; Chauvet M; Rabin L; Puteaud I; Duley S; Hamaidia S; Bruder J; Rolland-Neyret V; Le Gouill S; Tournilhac O; Voog E; Maisonneuve H; Jacob MC; Leroux D; Béné MC; Formisano-Tréziny C; Gabert J; Gressin R; Callanan MB
Br J Haematol; 2012 Jul; 158(2):186-197. PubMed ID: 22626453
[TBL] [Abstract][Full Text] [Related]
10. Cyclin D1 mRNA as a molecular marker for minimal residual disease monitoring in patients with mantle cell lymphoma.
Lokvenc M; Kalinova M; Forsterova K; Klener P; Trneny M; Fronkova E; Kodet R
Ann Hematol; 2018 Mar; 97(3):467-474. PubMed ID: 29273915
[TBL] [Abstract][Full Text] [Related]
11. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM; Kneba M
Methods Mol Biol; 2019; 1956():199-228. PubMed ID: 30779036
[TBL] [Abstract][Full Text] [Related]
12. Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression.
Zeng W; Fu K; Quintanilla-Fend L; Lim M; Ondrejka S; Hsi ED
Am J Surg Pathol; 2012 Feb; 36(2):214-9. PubMed ID: 22251940
[TBL] [Abstract][Full Text] [Related]
13. Polyclonal antibody targeting SOX11 cannot differentiate mantle cell lymphoma from B-cell non-Hodgkin lymphomas.
Zhang LN; Cao X; Lu TX; Fan L; Wang L; Xu J; Zhang R; Zou ZJ; Wu JZ; Li JY; Xu W
Am J Clin Pathol; 2013 Dec; 140(6):795-800. PubMed ID: 24225745
[TBL] [Abstract][Full Text] [Related]
14. SOX11, CCND1, BCL1/IgH and IgH-VDJ: a battle of minimal residual disease markers in mantle cell lymphoma?
Simonsen AT; Schou M; Sørensen CD; Bentzen HH; Nyvold CG
Leuk Lymphoma; 2015; 56(9):2724-7. PubMed ID: 25629991
[No Abstract] [Full Text] [Related]
15. [Expression of SOX11 mRNA in mantle cell lymphoma and its clinical significance].
Wang YY; Yu Z; Yi SH; Li ZJ; Li CH; Xie ZQ; Li F; Zang MR; Hao M; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2012 Jul; 33(7):556-60. PubMed ID: 22967417
[TBL] [Abstract][Full Text] [Related]
16. Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease.
Pott C; Schrader C; Brüggemann M; Ritgen M; Harder L; Raff T; Tiemann M; Dreger P; Kneba M
Eur J Haematol; 2005 Apr; 74(4):353-8. PubMed ID: 15777349
[TBL] [Abstract][Full Text] [Related]
17. Variant t(2;11)(p11;q13) associated with the IgK-CCND1 rearrangement is a recurrent translocation in leukemic small-cell B-non-Hodgkin lymphoma.
Wlodarska I; Meeus P; Stul M; Thienpont L; Wouters E; Marcelis L; Demuynck H; Rummens JL; Madoe V; Hagemeijer A
Leukemia; 2004 Oct; 18(10):1705-10. PubMed ID: 15306823
[TBL] [Abstract][Full Text] [Related]
18. Association of SOX11 gene expression withclinical features and prognosis of mantle cell lymphoma.
He JX; Xi YF; Su LP; Gao N; Xu EW; Xie LW; Wang LY; Zheng YP; Han WE; Chang J; Wang HW
Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2556-2563. PubMed ID: 29771407
[TBL] [Abstract][Full Text] [Related]
19. Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms.
Chen YH; Gao J; Fan G; Peterson LC
Mod Pathol; 2010 Jan; 23(1):105-12. PubMed ID: 19801969
[TBL] [Abstract][Full Text] [Related]
20. Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma.
Dalland JC; Smadbeck JB; Sharma N; Meyer RG; Pearce KE; Greipp PT; Peterson JF; Kumar S; Ketterling RP; King RL; Baughn LB
Genes Chromosomes Cancer; 2021 Oct; 60(10):678-686. PubMed ID: 34124820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
